# CytoMed Therapeutics Gets Nasdaq Notice Over $1 Bid Deficiency

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/29259
Published: 2026-10-09T20:51:27.000Z
Updated: 2026-10-09T20:51:27.000Z
Section: Business

> The company has until April 5, 2027, to restore compliance after its closing bid price remained below $1 for 30 consecutive business days.

CytoMed Therapeutics Limited (GDTC) received a Nasdaq noncompliance notice after its closing bid price remained below $1 for 30 consecutive business days.

The company has until April 5, 2027, to restore compliance with Nasdaq’s minimum bid-price requirement. It must maintain a closing bid price of at least $1 to meet the standard.

The notice concerns the company’s continued listing compliance and sets the April 5 deadline for corrective action.